PubMed Health⌕ Search

Biomedical subjects

H Rosenfeld

Publications and source records attributed to H Rosenfeld.

13 recordsLinked to original sources
PubMed1988

Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.

The uptake system for 6-diazo-5-oxo-L-norleucine (DON) was studied in mouse P388 leukemia cells. The DON transport system was found to resemble that of another glutamine antimetabolite, Acivicin, in its strong temperature dependence, utilization of the "L" transport system, inhibition by glutamine but not by glutamate, potent inhibition by p-chloromercuribenzene sulfonate, Na+, and only minimal inhibition by various energy poisons. A Km of approximately 70 microM and a Vmax of 3.4 nmoles/10(6) cells/min was calculated for this cell line. The accumulated DON was not metabolized by P388 cells and moderate efflux occurred at 37 degrees C. The DON transport characteristics of a DON-resistant P388 cell line (100 times ID50 of parent line) were similar to those of the DON-sensitive parent line, indicating that altered drug transport may not be involved in development of resistance to this antimetabolite. The finding that an Acivicin-resistant subline of P388 cells which exhibited good transport of DON showed negligible transport of Acivicin suggests different modes of resistance towards the two glutamine antimetabolites.

Animals↗
PubMed1988

The treatment of cutaneous vascular lesions with the Nd:YAG laser.

The Nd:YAG laser is well suited for the treatment of cutaneous vascular lesions. The characteristic properties of the Nd:YAG laser emissions in tissue are a high degree of penetration with low absorption by unpigmented tissue. The result is a coagulative effect on tissue containing hemoglobin with relative skin sparing. The Nd:YAG laser was used to treat 116 patients with a variety of cutaneous vascular lesions. Good to excellent results were obtained with a low complication rate for deep cavernous and capillary lesions, port wine stains, and minor vascular ectasias above the lower extremities. Minor venous ectasias and varicosities located on the lower extremities responded poorly. The Nd:YAG laser represents an efficacious tool for the treatment of difficult vascular lesions, with the exception of venous lesions of the lower extremities.

Facial Neoplasms↗
PubMed1988

Experience with the Nd:YAG laser in the treatment of keloid scars.

Numerous therapeutic modalities have been espoused for the treatment of keloids. In the laboratory, great strides have been made in understanding the connective tissue pathobiology that underlies this problem. Unfortunately, no consistent treatment has been found to prevent the development of surface overhealing. Moreover, all forms of therapy designed to treat this condition have produced inconsistent results. This article documents the use of the Nd:YAG laser in the treatment of 20 patients with keloid scars. Candidates for the study included patients with no previous therapy and those who had prior treatment with steroids and/or surgery with no improvement. Although the use of Nd:YAG laser for keloids continues to be investigational, our results appear promising. Success of therapy was judged by softening and flattening of the scar. Laboratory studies provide a basis for understanding the possible effect of connective tissue metabolism with the Nd:YAG.

Acne Vulgaris↗
PubMed1986

Brotizolam, a triazolothienodiazepine, in insomnia.

Sixty-three outpatients with chronic insomnia were treated for 3 weeks under double-blind conditions with either brotizolam (n = 29) at a dose of 0.25 mg or 0.5 mg or placebo (n = 34). A 3-day placebo period preceded and followed the double-blind treatment phase. Brotizolam consistently produced significantly more sleep improvement than placebo but also more adverse effects. In those patients switched abruptly from brotizolam to placebo, rebound insomnia was observed, being most marked at the first post-brotizolam placebo night.

Adult↗
PubMed1978

Relationship between maximal oxygen uptake and left ventricular function in exercise.

Left ventricular systolic time intervals (STI's), cardiac output, and arterial blood pressures were measured during bicycle ergometer work in three groups of 10 young men (aged 20-33 yr) who represented average (VO2max = 42-45 ml.kg-1.min-1), moderate (VO2max = 50-56 ml.kg-1.min-1), and high (VO2max = 59-72 ml.kg-1.min-1) levels of cardiovascular fitness. The subjects were studied using noninvasive procedures at steady-state heart rate of approximately 110, 130, and 150 beats.min-1. At all exercise levels, the fitter subjects displayed slightly shorter values for the preejection period (PEP) compared with less fit groups. Significantly (P less than 0.05) larger stroke volumes, longer left ventricular ejection times (LVET), faster mean systolic ejection rates and lower PEP/LVET ratios were found in the group with the highest aerobic capacity. Although these observations appear to indicate a superior mean level of left ventricular performance in groups who represent high levels of cardiovascular fitness, it was concluded that the use of STI values by themselves to describe the cardiovascular fitness of an individual would not be warranted.

Adult↗
PubMed1976

Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.

Emotional sympomatology data on 78 obese females treated for 3 weeks with fenfluramine, dextroamphetamine, or placebo were evaluated. These obese females were shown to be considerably less emotionally disturbed than neurotic females, and similar in emotional symptomatology to other females seeing physicians for nonpsychiatric complaints. Even within these marginally sympatomatic patients, fenfluramine and dextroamphetamine were significantly more effective than placebo in reducing anxious, depressive, and anxious-depressive symptomatology. Fenfluramine was particularly effective in alleviating anxiety in patients who were initially higher in anxiety. Most important, fenfluramine produced significantly greater weight loss than dextroamphetamine in patients with higher levels of anxiety and depression, while dextroamphetamine was an especially effective anorexic in low anxious patients. Differences in initial anxiety and depression, even within relatively normal patients, may well affect results obtained with fenfluramine and dextroamphetamine in the short-term treatment of obesity.

Adult↗
PubMed1976

Lorazepam and diazepam in anxious outpatients. A controlled study.

The response of 134 anxious neurotic outpatients to lorazepam, diazepam, and placebo was assessed in a 4-week double-blind trial. Both active drugs produced significantly more symptom reduction than placebo. Lorazepam, however, proved effective primarily in those patients who did not complain of sedation, and produced greatest improvement in initially sicker patients. Sedation was significantly more disturbing to lorazepam-treated patients than to diazepam-treated patients. Present findings suggested that 3 mg/day of lorazepam may be too high a dosage for mildly anxious patients, while 15 mg/day of diazepam seems an appropriate dosage for mildly anxious patients but may be too low a dosage for highly anxious patients.

Adult↗
PubMed1975

Triazolam in insomniac family practice patients.

Triazolam, 0.5 mg, a benzodiazepine with hypnotic properties, was compared to secobarbital, 100 mg, and placebo in a 1-wk study conducted with 100 insomniac family practice patients. Considerable sensitivity to differential treatment effects was demonstrated for these family practice patients as well as for a research methodology that combines a crossover design, permitting preference ratings, with a between-patient design. In almost all sleep parameters, assessed with a variety of subjective techniques, triazolam and secobarbital were shown to be significantly more effective than placebo. Triazolam was consistently and often significantly indicated to be a more effective hypnotic, particularly for reducing nocturnal awakening, than secobarbital. Analysis of self-report emotional distress data revealed that present insomniac patients were slightly more emotionally symptomatic than other nonpsychiatric populations. Triazolam was followed by the greatest and secobarbital the least relief of emotional symptoms and triazolam emerged as an especially effective hypnotic for initially more depressed insomniac patients. Present findings suggest that type and degree of emotional symptomatology may affect the response of insomniac patients to hypnotics.

Benzodiazepines↗
PubMedDate not supplied

Some therapeutic factors in psychoanalysis.

Several aspects of the patient-analyst interaction play an important part in the success or failure of analysis. Examining the unconscious and conscious attitude of the analyst in the therapeutic process clarifies the source of the analyst's difficulties in functioning successfully in his professional role. In the attitude which the analyst adopts toward his patients, it is essential, for example, to differentiate antitherapeutic factors such as the tendency of the analyst to collude with his patients from such therapeutic factors as sensitivity, receptiveness, and openness to the patients non verbal and verbal communications. These help the analyst to understand the patients on the level of object relation and ego function which is most meaningful to him. The analyst's peace of mind and his capacity to contain and bring together the patients fragmented mental state is of particular importance in the treatment of borderline and psychotic patients. Certain features in the patient's personality, such as the capacity for early object relations, sensitivity, and capacity for observation and perception, seem to contribute to a more open therapeutic interaction between patient and analyst. Nevertheless, difficulties in the interaction between patient and analyst remain and are a serious threat to the successful function of the psychoanalytic process.

Adolescent↗